Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report
Year: 2024
Type: article
Study design: Case Report
Abstract: Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM) with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical trials testing the efficacity of novel therapies in these patients. New immune approaches such as B-cell maturation antigen (BCMA) and G protein-coupled receptor, family C, group 5, member D (GPRC5D) -targeting agents, including chimeric antigen receptor (CAR) T-cells and bispecific antibodies could play a role in PCL treatment. However, PCL patients were excluded from recent pivotal clinical trials testing those agents and only some case reports have been published. We present here the clinical course of a patient with relapsed/refractory (R/R) primary (p) PCL who was treated with anti-BCMA and anti-GPRC5D bispecific antibodies at our center.
Source: Frontiers in Immunology
Authors: Chiara Bernardi, Yan Beauverd, Thien An Tran, Marie Maulini, Maria Mappoura, Sarah Morin, Federico Simonetta, Anne Cairoli, Holger W. Auner, Kaveh Samii, Yves Chalandon, Carmen de Ramon Ortiz
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,295
Funder: Université de Genève
OpenAlex ID: W4404866600